This "news feature" in the August issue of Nature
Post# of 148155
(Total Views: 926)
Posted On: 09/05/2021 1:43:53 PM
This "news feature" in the August issue of Nature Biotechnology on "Covid-19 Long Haulers" is more than a "nice mention" of leronlimab. Despite the FDA letter, this shows CytoDyn - even in Covid - can be discussed in the nicest of nice company. (A link to this was posted earlier.)
Along with being included in a table of only 7 drugs in long-hauler clinical trials, and Kelly being quoted saying the virus could enter human brains by traveling along the olfactory nerve, below is the main section on CytoDyn. Particularly note their positive phrasing about CD-12 results and note on CCR5 MOAs in general.
While slightly disappointing that this was written before the LH Phase 2 was finished, it indicates they will have interest.
"On the US West Coast, CytoDyn is testing its CC-motif chemokine receptor 5 (CCR5) antagonist leronlimab, ..., in a phase 2 trial with a target enrollment of 50 people. CCR5 is implicated in many disease processes, including HIV, multiple sclerosis and metastatic cancer.
CytoDyn’s marketing materials claim it helps to modulate immune cell trafficking to sites of inflammation. Leronlimab has already been tested in a phase 2b/3 clinical trial as add-on therapy for respiratory illness in patients critically ill with COVID-19. Results showed a survival benefit compared with commonly used treatments, and the current phase 2 will investigate the drug as treatment for wide-ranging symptoms.
In explaining the rationale for using leronlimab in long-COVID, Kelly says that CCR5 binding will help to regulate the immune response, so that macrophages and other immune cells “don’t rush in all at once and destroy tissue. We think we can coordinate immune tracking to slow inflammation.”"
https://www.nature.com/articles/s41587-021-00...Dba8z9hDjM
Along with being included in a table of only 7 drugs in long-hauler clinical trials, and Kelly being quoted saying the virus could enter human brains by traveling along the olfactory nerve, below is the main section on CytoDyn. Particularly note their positive phrasing about CD-12 results and note on CCR5 MOAs in general.
While slightly disappointing that this was written before the LH Phase 2 was finished, it indicates they will have interest.
"On the US West Coast, CytoDyn is testing its CC-motif chemokine receptor 5 (CCR5) antagonist leronlimab, ..., in a phase 2 trial with a target enrollment of 50 people. CCR5 is implicated in many disease processes, including HIV, multiple sclerosis and metastatic cancer.
CytoDyn’s marketing materials claim it helps to modulate immune cell trafficking to sites of inflammation. Leronlimab has already been tested in a phase 2b/3 clinical trial as add-on therapy for respiratory illness in patients critically ill with COVID-19. Results showed a survival benefit compared with commonly used treatments, and the current phase 2 will investigate the drug as treatment for wide-ranging symptoms.
In explaining the rationale for using leronlimab in long-COVID, Kelly says that CCR5 binding will help to regulate the immune response, so that macrophages and other immune cells “don’t rush in all at once and destroy tissue. We think we can coordinate immune tracking to slow inflammation.”"
https://www.nature.com/articles/s41587-021-00...Dba8z9hDjM
(20)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼